Introduction Founded in 2016, Yuheng Bio is a Chinese biopharmaceutical company with an international perspective. It specializes in the development, production, and sale of cancer drugs. After five years, Yingyi Bio commercialized its first drug, Sipali monoclonal injection, for relapsed or refractory classical Hodgkin lymphoma. The company aims to develop innovative biopharmaceutical products in partnership with domestic and international entities. |